Free Trial

Edesa Biotech (EDSA) Competitors

Edesa Biotech logo
$2.34 -0.09 (-3.70%)
(As of 02:41 PM ET)

EDSA vs. MRKR, PLUR, LGVN, IXHL, PMN, DARE, INKT, RNXT, LSB, and DRRX

Should you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include Marker Therapeutics (MRKR), Pluri (PLUR), Longeveron (LGVN), Incannex Healthcare (IXHL), ProMIS Neurosciences (PMN), Daré Bioscience (DARE), MiNK Therapeutics (INKT), RenovoRx (RNXT), Lakeshore Biopharma (LSB), and DURECT (DRRX). These companies are all part of the "pharmaceutical products" industry.

Edesa Biotech vs.

Edesa Biotech (NASDAQ:EDSA) and Marker Therapeutics (NASDAQ:MRKR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

In the previous week, Marker Therapeutics had 1 more articles in the media than Edesa Biotech. MarketBeat recorded 1 mentions for Marker Therapeutics and 0 mentions for Edesa Biotech. Marker Therapeutics' average media sentiment score of 0.96 beat Edesa Biotech's score of 0.62 indicating that Marker Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Edesa Biotech Positive
Marker Therapeutics Positive

Edesa Biotech has a net margin of 0.00% compared to Marker Therapeutics' net margin of -179.74%. Marker Therapeutics' return on equity of -89.63% beat Edesa Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Edesa BiotechN/A -137.95% -97.48%
Marker Therapeutics -179.74%-89.63%-71.62%

Edesa Biotech currently has a consensus price target of $21.00, indicating a potential upside of 797.44%. Marker Therapeutics has a consensus price target of $19.00, indicating a potential upside of 453.94%. Given Edesa Biotech's higher probable upside, equities analysts plainly believe Edesa Biotech is more favorable than Marker Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Edesa Biotech
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Marker Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

5.5% of Edesa Biotech shares are owned by institutional investors. Comparatively, 22.4% of Marker Therapeutics shares are owned by institutional investors. 25.0% of Edesa Biotech shares are owned by insiders. Comparatively, 17.4% of Marker Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Marker Therapeutics received 45 more outperform votes than Edesa Biotech when rated by MarketBeat users. However, 77.14% of users gave Edesa Biotech an outperform vote while only 63.72% of users gave Marker Therapeutics an outperform vote.

CompanyUnderperformOutperform
Edesa BiotechOutperform Votes
27
77.14%
Underperform Votes
8
22.86%
Marker TherapeuticsOutperform Votes
72
63.72%
Underperform Votes
41
36.28%

Marker Therapeutics has higher revenue and earnings than Edesa Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edesa BiotechN/AN/A-$8.37MN/AN/A
Marker Therapeutics$3.31M9.24-$8.24MN/AN/A

Edesa Biotech has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Marker Therapeutics has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500.

Summary

Marker Therapeutics beats Edesa Biotech on 9 of the 13 factors compared between the two stocks.

Get Edesa Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EDSA vs. The Competition

MetricEdesa BiotechPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$7.61M$6.69B$5.21B$9.15B
Dividend YieldN/A8.02%5.73%4.02%
P/E RatioN/A6.24103.2414.99
Price / SalesN/A324.451,247.4687.66
Price / CashN/A56.9841.6838.06
Price / Book1.005.314.734.93
Net Income-$8.37M$151.54M$119.24M$224.48M
7 Day Performance1.74%6.89%2.33%1.69%
1 Month Performance-12.69%3.82%1.88%8.93%
1 Year Performance-33.14%28.17%31.96%28.19%

Edesa Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EDSA
Edesa Biotech
2.5385 of 5 stars
$2.34
-3.7%
$21.00
+797.4%
-28.1%$7.61MN/A0.0020High Trading Volume
MRKR
Marker Therapeutics
4.2543 of 5 stars
$3.49
-0.3%
$19.00
+444.4%
+25.5%$31.13M$3.31M0.0060Positive News
Gap Down
PLUR
Pluri
N/A$5.52
-1.4%
N/A+7.9%$30.69M$598,000.00-0.91150
LGVN
Longeveron
3.5891 of 5 stars
$2.05
flat
$8.00
+290.2%
-90.2%$30.42M$1.89M-0.3323
IXHL
Incannex Healthcare
0.7744 of 5 stars
$1.72
-3.4%
N/A-75.2%$30.35M$86,000.00-1.253News Coverage
PMN
ProMIS Neurosciences
1.2789 of 5 stars
$0.92
-1.9%
N/A-19.5%$30.14M$10,000.00-9.406Gap Up
DARE
Daré Bioscience
2.6856 of 5 stars
$3.39
-1.2%
$24.00
+608.0%
-27.0%$29.49M$2.81M-5.7930Positive News
INKT
MiNK Therapeutics
2.1335 of 5 stars
$0.74
+0.8%
$6.50
+779.9%
-33.9%$29.22MN/A-1.8830Gap Up
RNXT
RenovoRx
1.6733 of 5 stars
$1.20
-5.5%
$6.13
+410.4%
+83.1%$28.80MN/A-2.216News Coverage
Gap Up
LSB
Lakeshore Biopharma
0.6122 of 5 stars
$3.09
+12.4%
N/AN/A$28.76M$573.42M0.00773Gap Down
DRRX
DURECT
3.5985 of 5 stars
$0.92
+4.5%
$5.00
+443.5%
+24.8%$28.56M$8.55M-1.5080Analyst Forecast
Gap Down

Related Companies and Tools


This page (NASDAQ:EDSA) was last updated on 12/5/2024 by MarketBeat.com Staff
From Our Partners